RP-5063

RP-5063
Clinical data
Routes of
administration		 Oral
Identifiers
DrugBank DB09226

RP-5063, also known as RP-5000, is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder.[1][2][3][4] Reviva Pharmaceuticals also intends to investigate RP-5063 for the treatment of bipolar disorder, major depressive disorder, psychosis/agitation associated with Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder (ADD/ADHD), and autism.[5][6] As of May 2015, it is in phase III clinical trials for schizophrenia.[5][6]

Pharmacodynamics

RP-5063 is frequently described as a so-called "dopamine-serotonin system stabilizer" due to its unique actions on the dopamine and serotonin neurotransmitter systems compared to other antipsychotics.[4][7] Specifically, it acts as a partial agonist of the D2, D3, and D4 receptors and of the 5-HT1A and 5-HT2A receptors, and as an antagonist of the 5-HT6 and 5-HT7 receptors.[3][4][7] RP-5063 has high affinity for the D2S, D2L, D3, D4.4, 5-HT1A, 5-HT2A, 5-HT7, and H1 receptors, and moderate affinity for the D1, D5, 5-HT3, 5-HT6 receptors, the SERT, and the α1B-adrenergic receptor.[7] It lacks significant affinity for the 5-HT1B, 5-HT2C, α2-adrenergic, and mACh receptors, as well as for the NET and DAT.[7][8]

See also

References

  1. ↑ Medicines in Development for Mental Health (PDF) (Report). Pharmaceutical Research and Manufacturers of America. 2014. p. 20. Retrieved 2015-05-19.
  2. ↑ Köster, Luisa-Sophie; Carbon, Maren; Correll, Christoph U (2014). "Emerging drugs for schizophrenia: an update". Expert Opinion on Emerging Drugs. 19 (4): 511–531. doi:10.1517/14728214.2014.958148. ISSN 1472-8214.
  3. 1 2 "Drug Development in Schizophrenia: Summary and Table". Pharmaceutical Medicine. 28 (5): 265–271. 2014. doi:10.1007/s40290-014-0070-6. ISSN 1178-2595.
  4. 1 2 3 Cantillon, Marc (2014). "Efficacy and Safety of Novel Dopamine Serotonin Stabilizer RP 5063 in Acute Schizophrenia and Schizoaffective Disorder". Schizophrenia Research. 153: S22. doi:10.1016/S0920-9964(14)70070-2. ISSN 0920-9964.
  5. 1 2 "About Us". Reviva Pharmaceuticals. Retrieved 2015-05-19.
  6. 1 2 "Product Pipeline". Reviva Pharmaceuticals. Retrieved 2015-05-19.
  7. 1 2 3 4 Marc Cantillon, M.D., Mike Li, MS, Sarath Kanekal, Ph.D., DABT, RAC, Robert M.J. Ings, Ph.D., Grace Tung, RAC, Laxminarayan Bhat (2013). "Refresh: A Phase 2 RP5063 Efficacy and Safety in Schizophrenia and Schizoaffective Disorder" (PDF). American Society of Clinical Psychopharmacology. Retrieved 2015-05-19.
  8. ↑ Reviva Pharmaceuticals (2012). "Reviva Pharmaceuticals Announces Enrollment of Patients in Phase 2 Clinical Study of RP5063 for the Treatment of Schizophrenia and Schizoaffective Disorder". PipelineReview.


This article is issued from Wikipedia - version of the 6/12/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.